Research

*January 2025* Data from a pooled analysis evaluating sunvozertinib (formerly DZD9008) show promising antitumor activity with a favorable safety profile for EGFR- tyrosine kinase inhibitor (TKI)-resistant non–small cell lung cancer (NSCLC). The pooled data come from 3 studies: the multinational phase 2 WU-KONG1 trial (NCT03974022), the phase 1 WU-KONG2 trial…

*January 2025* Key Takeaways Zipalertinib demonstrated a 40% ORR and 90% DCR in NSCLC patients with EGFR exon 20 insertion mutations, meeting the trial's primary endpoint. Patients previously treated with amivantamab showed a higher ORR of 50%, indicating potential efficacy in this subgroup. Common treatment-related adverse effects included rash, paronychia,…

*January 2025* Abstract Introduction Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced NSCLC as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reaction (IRR) rate. Methods The phase 2 SKIPPirr study (NCT05663866) enrolled participants with EGFR-mutated (exon 19 deletion…

*January 2025* Treatments are rapidly evolving in the second-line setting and beyond for patients with HER2-mutated non–small cell lung cancer (NSCLC), with several promising TKIs under development looking to join fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in this setting. Following standard of care (SOC) systemic frontline therapy, T-DXd is the NCCN guideline…

*September 2024* The Young Lung Cancer Initiative hosted a webinar with Dr. Laura Petrillo, who is a palliative care physician at MGH in Boston, MA. She is the Principal Investigator of the POISE study ("Patient-centered, Optimal Integration of Survivorship and Palliative Care") for people living with advanced lung cancer receiving…

*January 2025* The FDA has accepted and granted priority review to the biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd). This investigational treatment is intended for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have previously received systemic therapies, including EGFR-targeted treatments. The FDA’s decision…

*May 2025* Highlights •Patients with EGFR-mutated NSCLC that progresses after osimertinib treatment need additional treatment options. •c-Met protein expression correlates with osimertinib resistance. •Teliso-V is an antibody–drug conjugate that targets c-Met protein overexpression. •Teliso-V + osimertinib had promising activity in EGFR-mut, c-Met protein-overexpressing NSCLC post-osimertinib progression. •The combination of Teliso-V…

*February 2025* In this video, Mara B. Antonoff, MD, FACS, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to discuss a session on operating in stage IV lung cancer held at the 61st Annual Meeting of the Society of Thoracic Surgeons (STS) in Los Angeles.…